ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 3.6% on Insider Selling

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) were down 3.6% during mid-day trading on Monday following insider selling activity. The stock traded as low as $79.36 and last traded at $79.8450. Approximately 86,438 shares traded hands during trading, a decline of 77% from the average daily volume of 377,608 shares. The stock had previously closed at $82.85.

Specifically, SVP Krista Davis sold 1,622 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80. Following the completion of the transaction, the senior vice president directly owned 58,564 shares in the company, valued at $4,825,673.60. The trade was a 2.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Analyst Ratings Changes

ANIP has been the topic of a number of research analyst reports. Guggenheim raised their target price on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a report on Monday, November 10th. HC Wainwright upped their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Barclays initiated coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price objective on the stock. Truist Financial lifted their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, October 9th. Finally, Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $102.14.

ANI Pharmaceuticals Stock Down 3.6%

The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of 49.04 and a beta of 0.48. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The stock has a 50 day moving average price of $86.70 and a 200 day moving average price of $81.62.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. During the same quarter last year, the business earned $1.34 EPS. The firm’s quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Intech Investment Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 134.7% in the 2nd quarter. Intech Investment Management LLC now owns 26,917 shares of the specialty pharmaceutical company’s stock worth $1,756,000 after purchasing an additional 15,447 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in ANI Pharmaceuticals by 59.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,326 shares of the specialty pharmaceutical company’s stock valued at $674,000 after purchasing an additional 3,869 shares in the last quarter. Squarepoint Ops LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth $2,137,000. Dynamic Technology Lab Private Ltd acquired a new position in ANI Pharmaceuticals during the second quarter worth $209,000. Finally, Sio Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 29.4% in the second quarter. Sio Capital Management LLC now owns 112,923 shares of the specialty pharmaceutical company’s stock valued at $7,368,000 after buying an additional 25,625 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.